Professor, Radiation Oncology
Thoracic Oncology Program
UNC Breast Center
Area of Interest
Dr. Rosenman’s area of research interest is in high performance computing in radiation cancer treatment and real-time display of 3d radiation doses. Dr. Rosenman, along with Drs. Mark Socinski from Medical Oncology, Frank Detterbeck from Thoracic Surgery, and Patricia Rivera from Pulmonary Medicine, has continued the development of a highly successful multidisciplinary Thoracic Oncology program. The combined efforts of these doctors have placed new patients (237 since 1995) onto Lineberger, Cooperative Group, or pharmaceutical company sponsored studies. This has provided a comprehensive clinical and research base for these important and common malignancies. Forty-three patients have been enrolled onto LCC # 9603, a trial evaluating the administration of carboplatin and paclitaxel followed by escalating doses of conformal irradiation for patients with unresectable stage III NSCLC. This trial has incorporated Dr. Rosenman’s expertise as a national leader in the development of these techniques for patients with lung cancer and other solid tumors.
As a result of this group’s work, the UNC Lineberger Comprehensive Cancer Center is currently serving as the lead institution for multi-center Phase III studies in small cell and non-small cell lung cancer. The non-small cell study will address the important question of optimal duration of therapy for patients with metastatic disease by asking whether or not continued therapy until progression is a more effective strategy than stopping treatment after an initial four cycle course of treatment. This program has also taken the lead in developing an active relationship with Carolinas Medical Center in Charlotte, N.C. This clinical research affiliation has led to enhanced patient accrual onto several active lung cancer studies, which Drs. Socinski and Rosenman are chairing. Work by Dr. Rosenman in the development of conformal radiotherapy techniques has been crucial in developing the affiliation with investigators at the Carolinas Medical Center for lung cancer studies